EGFR and non-small cell lung carcinoma: The preliminary results of a recent clinical study NCT01405079 in NSCLC stage II–IIIa patients with EGFR mutation treated with gefitinib versus vinorelbine/platinum indicated that patients on adjuvant gefitinib have a better disease-free survival (DFS) than those on chemotherapy (38.7 months vs. 18 months) [41].